Print PDF

Sheppard Mullin Represented Laidlaw in Connection with NLS Pharmaceuticals’ Private Placements


Sheppard Mullin served as counsel to Laidlaw & Company (UK) Ltd., as introducing broker, in connection with NLS Pharmaceuticals’, a Swiss clinical-stage biopharmaceutical company, $30 million private placement with marquee life sciences investor, Biotechnology Value Fund, BVF Partners L.P. The transaction closed on December 13, 2022.

Sheppard Mullin also represented Laidlaw, as sole placement agent, in NLS Pharmaceuticals' $4 million private placement with investors, alongside participation from the company's Chairman of the Board of Directors, Ronald Hafner, and George Apostol, the company's recently appointed Chief Medical Officer. This transaction closed on October 7, 2022.

The Sheppard Mullin deal team was led by Richard Friedman and included Stephen Cohen and Gregory Carney.

Click here and here to view the press releases.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.